Nicoderm Cq is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is protected by 5 US drug patents filed from 2013 to 2015 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 22, 2021. Details of Nicoderm Cq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8075911 | Transparent transdermal nicotine delivery devices |
May, 2021
(3 years ago) |
Expired
|
| US8999379 | Transparent transdermal nicotine delivery devices |
Feb, 2020
(4 years ago) |
Expired
|
| US8663680 | Transparent transdermal nicotine delivery devices |
Feb, 2020
(4 years ago) |
Expired
|
| US9205059 | Transparent transdermal nicotine delivery devices |
Dec, 2019
(5 years ago) |
Expired
|
| US5508038 | Polyisobutylene adhesives for transdermal devices |
Apr, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nicoderm Cq's patents.
Latest Legal Activities on Nicoderm Cq's Patents
Given below is the list of recent legal activities going on the following patents of Nicoderm Cq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 15 Jan, 2024 | US8075911 |
| Expire Patent Critical | 15 Jan, 2024 | US9205059 |
| Maintenance Fee Reminder Mailed Critical | 31 Jul, 2023 | US8075911 |
| Maintenance Fee Reminder Mailed Critical | 31 Jul, 2023 | US9205059 |
| Expire Patent Critical | 15 May, 2023 | US8999379 |
| Maintenance Fee Reminder Mailed Critical | 28 Nov, 2022 | US8999379 |
| Expire Patent Critical | 11 Apr, 2022 | US8663680 |
| Maintenance Fee Reminder Mailed Critical | 25 Oct, 2021 | US8663680 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 May, 2019 | US8075911 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 May, 2019 | US9205059 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Nicoderm Cq and ongoing litigations to help you estimate the early arrival of Nicoderm Cq generic.
Nicoderm Cq's Litigations
Nicoderm Cq been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 28, 2010, against patent number US8075911. The petitioner , challenged the validity of this patent, with Robert M. Gale as the respondent. Click below to track the latest information on how companies are challenging Nicoderm Cq's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8075911 | June, 2010 |
Decision
(25 May, 2011) | Robert M. Gale | |
US patents provide insights into the exclusivity only within the United States, but Nicoderm Cq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nicoderm Cq's family patents as well as insights into ongoing legal events on those patents.
Nicoderm Cq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nicoderm Cq's generic launch date based on the expiry of its last outstanding patent is estimated to be May 22, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nicoderm Cq Generic API suppliers:
Nicotine is the generic name for the brand Nicoderm Cq. 1 company has already filed for the generic of Nicoderm Cq. Check out the entire list of companies who have already received approval for Nicoderm Cq's generic
How can I launch a generic of Nicoderm Cq before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Nicoderm Cq's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Nicoderm Cq's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Nicoderm Cq -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 7 mg/24 hrs 14 mg/24 hrs 21 mg/24 hrs | 30 May, 2014 | 1 | 22 May, 2021 | Extinguished |
Alternative Brands for Nicoderm Cq
Nicoderm Cq which is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation., has several other brand drugs using the same active ingredient (Nicotine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nicotine, Nicoderm Cq's active ingredient. Check the complete list of approved generic manufacturers for Nicoderm Cq
About Nicoderm Cq
Nicoderm Cq is a drug owned by Chattem Inc Dba Sanofi Consumer Healthcare. It is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation. Nicoderm Cq uses Nicotine as an active ingredient. Nicoderm Cq was launched by Chattem Sanofi in 1996.
Approval Date:
Nicoderm Cq was approved by FDA for market use on 02 August, 1996.
Active Ingredient:
Nicoderm Cq uses Nicotine as the active ingredient. Check out other Drugs and Companies using Nicotine ingredient
Treatment:
Nicoderm Cq is used for reducing withdrawal symptoms and nicotine cravings during smoking cessation.
Dosage:
Nicoderm Cq is available in film, extended release form for transdermal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 14MG/24HR | FILM, EXTENDED RELEASE | Over the counter | TRANSDERMAL |
| 7MG/24HR | FILM, EXTENDED RELEASE | Over the counter | TRANSDERMAL |
| 21MG/24HR | FILM, EXTENDED RELEASE | Over the counter | TRANSDERMAL |